PEOPLE

Kurt R. Brunden, PhD

Research Professor of Pathology and Laboratory Medicine
University of Pennsylvania Perelman School of Medicine

Contact InformationCenter for Neurodegenerative Disease Research
University of Pennsylvania
3600 Spruce St.
3rd Floor Maloney Bldg.
Philadelphia, PA 19104
Office: 215-615-5262

Email: kbrunden@upenn.edu

Specialty Division

Immunobiology and Experimental Pathology

Research Expertise

Dr. Brunden oversees research programs directed towards the identification of therapeutic targets and treatments for Alzheimer's, Parkinson's and other neurodegenerative diseases.

Itmat Expertise

Dr. Brunden oversees research programs directed towards the identification of therapeutic targets and treatments for Alzheimer's, Parkinson's and other neurodegenerative diseases.

Education

B.S. (Biology/Health Chemistry), Western Michigan University, 1980
Ph.D. (Biochemistry), Purdue University, 1985

Specialty Certification

Postgraduate Training

Post-docotoral fellow, Mayo Clinic and Foundation, 1985-1987
Instructor and Research Assoc., Mayo Clinic and Foundation, 1988-1988

Awards and Honors

Graduated Magna Cum Laude; 1980; Western Michigan University; Kalamazoo, MI, 1980
Merck Award; Department of Chemistry; Western Michigan University, Kalamazoo, MI, 1980
N.I.H. Competitive Predoctoral Training Award; Purdue University, West Lafayette, IN, 1981-1984
Outstanding Research Award; Department of Neurology; Mayo Clinic,
Rochester, MN, 1987
Travel Award; American Society for Neurochemistry, 1988

Memberships and Professional Organizations

Society for Neuroscience, 1991 - Present
American Association for the Advancement of Science, 1992 - 2008
American Chemical Society, 2005 - 2008
Chartered Member, NIH NINDS NSD-C Study Section, 2009 - 2012
Scientific Review Board, Alzheimer's Disease Drug Discovery Foundation, 2010 - Present
Chair, NIH NINDS NSD-C Study Section, 2010 - 2012
NIH-NCATS Therapeutics Discovery Special Emphasis Panel, 2012 - Present
NIH NINDS NSD-A Study Section, 2014 - 0214
NIH NIA U01 Drug Development Study Section, 2015 - Present
NIH NINDS Epilepsy CWOW Study Section, 2015 - 2015

Selected Publications

Evaluation of the brain-penetrant microtubule-stabilizing agent, dictyostatin, in the PS19 tau transgenic mouse model of tauopathy.

Makani V, Zhang B, Han H, Yao Y, Lassalas P, Lou K, Paterson I, Lee VM-Y, Trojanowski JQ, Ballatore C, Smith AB III and Brunden KR, Acta Neuropathol. Comm. In press(): , 2016

Characterization of brain-penetrant pyrimidine-containing molecules with differential microtubule-stabilizing activities developed as potential therapeutic agents for Alzheimer’s disease and related tauopathies

Kovalevich J, Cornec A-S, Yao Y, James M, Crowe A, Lee VM-Y, Trojanowski JQ, Smith AB III, Ballatore C and Brunden KR, J. Pharm. Exp. Therap. 357(): 432-450, 2016

The dynamics and turnover of tau aggregates in cultured cells: insights into therapies for tauopathies.

Guo JL, Buist A, Soares A, Callaerts K, Calafate S, Stevenaert F, Daniels JP, Zoll BE, Crowe A, Brunden KR, Moechers D and Lee V-MY, J. Biol. Chem. 291(): 13175-13193, 2016

Inflammatory eicosanoids increase amyloid precursor protein expression via activation of multiple neuronal receptors.

Herbst-Robinson KJ, Liu L, James M, Yao Y, Xie SX and Brunden KR, Scientific Reports 5(): 18286, 2015

Passive immunization with phospho-tau antibodies reduces tau pathology and functional deficits in two distinct mouse tauopathy models.

Sankaranaraynan S, Barten D, Vana L, Devidze N, Yang L, Cadelina G, Hoque N, DeCarr L, Kennan S, Lin A, Cao Y, Snyder B, Zhang B, Nitla M, Hirschfeld G, Barrezueta N, Polson C, Wes P, Rangan V, Cacace A, Albright CF, Meredith J, Trojanowski JQ, Lee V-MY, Brunden KR* and Ahlijanian M* (*Co-corresponding authors), PlosONE 10(): e0125614, 2015

Intracerebral injection of preformed synthetic tau fibrils initiates widespread tauopathy and neuronal loss in the brains of tau transgenic mice.

Peeraer E, Bottelbergs A, Van Kolen K, Stancu IC, Vasconcelos B, Mahieu M, Duytschaever H, Ver Donck L, Torremans A, Sluydts E, Van Acker N, Kemp JA, Mercken, M, Brunden KR, Trojanowski JQ, Dewachter I; Lee VM and Moechers D, Neurobiol. Dis. 73(): 83-95, 2015

Pharmacokinetic, pharmacodynamic and metabolic characterization of a brain retentive microtubule (MT)-stabilizing triazolopyrimidine.

Cornec A-S, James M, Kovalevich J, Trojanowski JQ, Lee VM-Y, Smith AB III, Ballatore C and Brunden KR, Bioorg. Med. Chem. Lett. in press(): , 2015

Brain-penetrant, orally bioavailable microtubule-stabilizing small molecules are potential candidate therapeutics for Alzheimer’s disease and related tauopathies.

65. Lou K, Yao Y, Hoye A, James M, Cornec A, Hyde E, Gay B, Lee VM-Y, Trojanowski JQ, Smith AB III, Brunden KR* and Ballatore C* (*Co-corresponding authors), J. Med. Chem. 57(): 6116-27, 2014

Potent, long-acting cyclopentane-1,3-dione thromboxane (A2) receptor antagonists.

66. Wang X, Liu L, Huang L, Herbst-Robinson K, Cornec A, James M, Sugiyama S, Bassetto M, Brancale A, Trojanowski JQ, Lee VM-Y, Smith AB III, Brunden KR* and Ballatore C* (*Co-corresponding authors), ACS Med. Chem. Lett. 5(): 1015-20, 2014

Evaluation of the cyclopentane-1,2-dione as a potential bio-isostere of the carboxylic acid functional group.

Ballatore C, Gay B, Huang L, Herbst-Robinson K, James M, Trojanowski JQ, Lee VM-Y, Brunden KR and Smith AB III, Bioorg. Med. Chem. Lett. 24(): 4171-75, 2014